ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tivunatamig

Also written as “PF-08634404” and “SSGJ-707”.

In Pfizer’s pipeline, PD-1xVEGF Bispecific Antibody. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Endometrial Neoplasms · Colorectal Neoplasms · Stomach Neoplasms, led by 2 companies.

Drug pageAnti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 28, 202515 company-led studies, 14 open or runningLicense: 3SBio → Pfizer, May 2025Next primary completion: Oct 18, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only1010 open or runningphase 3since Oct 28, 2025Oct 28, 2025Oct 18, 2027phase 2 · NCT07227012
3SBio54 open or runningphase 3since May 12, 2025Apr 8, 2024none ahead
  • Named in Pfizer’s own pipeline as tivunatamig PF-08634404, phase 3, as of Nov 3, 2026 (source).

Also a collaborator on its studies: Astellas Pharma.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of 3SBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Apr 8, 2024First studies: 2 phase 2 studiesFirst studyNCT06361927, NCT06412471
  2. Jun 25, 2024Phase 2 study in Colorectal NeoplasmsNCT06493760 · 130 planned · China
  3. Jul 22, 2024Phase 2 study in Endometrial NeoplasmsNCT06522828 · 80 planned · China
  4. May 12, 2025Phase 3 study in Advanced Non-Small Cell Lung CancerNCT06980272 · 3 enrolled · China
  5. May 19, 2025Pfizer licensed it from 3SBioLicenseEverywhere outside China, with an option on China · announced · Pfizer (release)
  6. Jul 19, 2026Named tivunatamigINNProposed as its International Nonproprietary Name in WHO's List 135 · before, PF-08634404, SSGJ-707
  7. Nov 18, 2026Phase 3 study terminatedStudy stoppedNCT06980272 · “Sponsor decided”

TargetBeta

“PD-1xVEGF Bispecific Antibody”the company's pipeline, read by Claude · source
“A humanized immunoglobulin G4 (IgG4) bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and an…”NCIt, read by Claude
“A humanized immunoglobulin G4 (IgG4) bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human vascular endothelial growth factor (VEGF), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
ABBV-1480RemeGenphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Merckphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039AruleMinghui Pharmaceuticalphase 23
Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rulewigen-biomedicine-technology-shanghai-co-ltdphase 22
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rulecompass-therapeuticsphase 11

Studies

All 5 3SBio leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06980272Advanced Non-Small Cell Lung Cancer · China3TerminatedFeb 1, 20263
NCT06522828Endometrial Neoplasms · China2RecruitingAug 202580
NCT06493760Colorectal Neoplasms · China2RecruitingJun 2025130
NCT06412471First-line Advanced NSCLC Patients · China2RecruitingJul 2025235
NCT06361927NSCLC · China2RecruitingJun 2025120

How it is read

Names in the registry

  • “PF-08634404”, 10 entries
  • “SSGJ-707”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.